Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaforte (malaysia) sdn. bhd. - megestrol acetate -

Canada - English - Health Canada

linson pharma co. - megestrol acetate - tablet - 40mg - megestrol acetate 40mg - antineoplastic agents

Canada - English - Health Canada

linson pharma co. - megestrol acetate - tablet - 160mg - megestrol acetate 160mg - antineoplastic agents

Canada - English - Health Canada

pro doc limitee - megestrol acetate - tablet - 40mg - megestrol acetate 40mg - antineoplastic agents

Canada - English - Health Canada

pro doc limitee - megestrol acetate - tablet - 160mg - megestrol acetate 160mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

stat rx usa llc - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 40 mg in 1 ml - megestrol acetate oral suspension usp contains megestrol acetate, a synthetic derivative of the naturally occurring steroid hormone, progesterone. megestrol acetate is a white, crystalline solid chemically designated as pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-. solubility at 37°c in water is 2 mcg per ml, solubility in plasma is 24 mcg per ml. its molecular weight is 384.51. the molecular formula is c24 h32 04 and the structural formula is represented as follows: megestrol acetate oral suspension is supplied as an oral suspension containing 40 mg of micronized megestrol acetate per ml. megestrol acetate oral suspension contains the following inactive ingredients: citric acid, lemon-lime flavor, microcrystalline cellulose/carboxymethylcellulose, purified water, sodium benzoate, sodium citrate, and sucrose. the suspension meets the requirements of usp dissolution test 3 in the usp monograph for megestrol acetate oral suspension, usp

United States - English - NLM (National Library of Medicine)

natco pharma usa llc - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate oral suspension, usp is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy.

United States - English - NLM (National Library of Medicine)

endo pharmaceuticals inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace es is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). limitations of use therapy with megace es for weight loss should only be insti­tuted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megace es is not intended for prophylactic use to avoid weight loss. - history of hypersensitivity to megestrol acetate or any component of the formulation. - pregnancy [see warnings and precautions (5.2), use in specific populations (8.1, 8.3)]. risk summary based on animal data, megestrol acetate may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see contraindications (4)] . there are no available human data to assess for any drug-associated risks of miscar

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - other treatable causes prophylactic use megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. megestrol acetate has had limited use in hiv infected women. all 10 women in the clinical trials reported breakthrough bleeding. megace® es is a progesterone derivative, which may induce vaginal bleeding in women.

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - other treatable causes prophylactic use megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. megestrol acetate has had limited use in hiv infected women. all 10 women in the clinical trials reported breakthrough bleeding. megace es is a progesterone derivative, which may induce vaginal bleeding in women. ®